RVTY Revvity, Inc.
USHealthcareAs of 2026-07-09 16:00
Why RVTY matters now
Revvity, Inc. (RVTY) is a US stock in Healthcare. The latest InvestLog snapshot shows $112.95 with +3.29% on the session and $12.60B in market capitalization; recent performance reads 1-month +4.31% and YTD +3.36%.
The latest financial table shown here is Q1 2026, with revenue of $711.1M, net income of $40.7M, and EPS of $0.36. Investors can compare that operating picture with valuation signals such as P/E 40.61 and FCF yield 4.4%.
The latest indexable market news headline is "Revvity to Hold Earnings Call on Tuesday, August 4, 2026" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $111.00; recent insider activity includes Gonzales Anita filing F-InKind; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
40.61
PEG
—
P/B
1.56
P/S
3.84
EV/EBITDA
17.66
DCF Value
$105.14
FCF Yield
4.4%
Div Yield
0.3%
Margins & Returns
Gross Margin
51.4%
Operating Margin
12.4%
Net Margin
8.3%
ROE
3.3%
ROA
2.0%
ROIC
2.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $711.1M | $40.7M | $0.36 |
| Q4 2025 | $772.1M | $98.4M | $0.87 |
| FY 2025 | $2.86B | $241.7M | $2.08 |
| Q3 2025 | $698.9M | $46.7M | $0.40 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$109.83
Target (Median)
$111.00
Target Range
$95.00 - $124.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.11
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.